AR126183A1 - Terapia de combinación anti-hcv ventajosa - Google Patents

Terapia de combinación anti-hcv ventajosa

Info

Publication number
AR126183A1
AR126183A1 ARP220101612A ARP220101612A AR126183A1 AR 126183 A1 AR126183 A1 AR 126183A1 AR P220101612 A ARP220101612 A AR P220101612A AR P220101612 A ARP220101612 A AR P220101612A AR 126183 A1 AR126183 A1 AR 126183A1
Authority
AR
Argentina
Prior art keywords
combination therapy
advantageous anti
hcv combination
compound
well
Prior art date
Application number
ARP220101612A
Other languages
English (en)
Inventor
Jean Sommadossi
- Moussa Adel Pierre
Keith M Pietropaolo
xiao-jian Zhou
Original Assignee
Atea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atea Pharmaceuticals Inc filed Critical Atea Pharmaceuticals Inc
Publication of AR126183A1 publication Critical patent/AR126183A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una combinación farmacéutica sinérgica del Compuesto 1 o una sal farmacéuticamente aceptable de este (p. ej., Compuesto 1-A) y Compuesto 2 o una sal farmacéuticamente aceptable de este, así como sus usos para tratar la hepatitis C o una afección relacionada a la hepatitis C, así como métodos para producir la combinación farmacéutica.
ARP220101612A 2021-06-17 2022-06-21 Terapia de combinación anti-hcv ventajosa AR126183A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163212047P 2021-06-17 2021-06-17

Publications (1)

Publication Number Publication Date
AR126183A1 true AR126183A1 (es) 2023-09-27

Family

ID=84526738

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101612A AR126183A1 (es) 2021-06-17 2022-06-21 Terapia de combinación anti-hcv ventajosa

Country Status (3)

Country Link
AR (1) AR126183A1 (es)
TW (1) TW202317145A (es)
WO (1) WO2022266497A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130273005A1 (en) * 2010-12-20 2013-10-17 Gilead Sciences, Inc. Methods for treating hcv
WO2014110687A1 (en) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2017023714A1 (en) * 2015-08-04 2017-02-09 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
GEP20237457B (en) * 2017-02-01 2023-01-10 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for treatment of hepatitis c virus
JP2022510014A (ja) * 2018-12-05 2022-01-25 アテア ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎ウイルスの治療のための高活性な合剤

Also Published As

Publication number Publication date
WO2022266497A1 (en) 2022-12-22
TW202317145A (zh) 2023-05-01

Similar Documents

Publication Publication Date Title
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CL2022001625A1 (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
ECSP22023220A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
UY38483A (es) Heterociclos funcionalizados como agentes antivirales
ECSP22071009A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
AR100006A1 (es) Derivados de tubulisina
CR20140086A (es) Tratamientos de combinación para hepatitis c
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
DOP2020000160A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CR20160483A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
CO2021000923A2 (es) Formulaciones de un inhibidor de axl/mer
AR122352A1 (es) Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este
AR119159A1 (es) Tratamientos de angioedema
UY39786A (es) Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
CU20190042A7 (es) Compuestos derivados de naftiridinona
UY37745A (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
AR126183A1 (es) Terapia de combinación anti-hcv ventajosa
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
CL2023000418A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos